Background In recent years, both methamphetamine use and STIs have been on the rise in the USA. In this analysis, we sought to ascertain whether the risk of STIs and HIV among methamphetamine users was moderated on the basis of participation in substance use treatment programmes.
Methods Data came from the National Survey on Drug Use and Health, 2015–2019. Among adult participants, survey-weighted logistic regression analyses were used to assess the relationship between past year methamphetamine use and risk of HIV and STIs, stratified by methamphetamine treatment utilisation and adjusted for demographic and other risk factors.
Results Among participants in the analytic sample (n=210 392), 1862 (0.9%) reported past year methamphetamine use, 566 (0.3%) reported receiving treatment for its use, 5471 (2.6%) tested positive for any STI in the past year and 395 (0.2%) for HIV ever in their lifetime. Past year methamphetamine use was associated with increased risk of STIs among those who did not receive treatment (adjusted OR=3.628; 95% CI 2.75 to 4.92). Significant moderation was also present between past-year methamphetamine use, risk of STI, and substance use treatment.
Conclusion In this analysis, we demonstrated a strong relationship between methamphetamine use and risk of STIs that differed based on receipt of substance use treatment. These findings suggested that integrated STI and substance use treatment programmes may yield substantial public health benefits.
- chlamydia Infections
- substance-related disorders
Data availability statement
Data are available in a public, open access repository. https://nsduhweb.rti.org/respweb/homepage.cfm.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Handling editor Adam Huw Bourne
Contributors All authors worked together to conceive of the manuscript. JPS led the writing of the manuscript. EM led statistical analyses and assisted with writing of the manuscript. CD contributed to the analyses and assisted with the writing and editing of the manuscript. EM is responsible for the overall content as guarantor.
Funding This work was supported by grants from the National Institute on Drug Abuse at the National Institutes of Health (K01DA046716, Principal Investigator: CD).
Disclaimer The sponsor had no involvement in the conduct of the research or the preparation of the article.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute on Drug Abuse or the National Institutes of Health.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.